193 related articles for article (PubMed ID: 35457286)
1. The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines.
Ghemrawi R; Khair M; Hasan S; Aldulaymi R; AlNeyadi SS; Atatreh N; Ghattas MA
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457286
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
6. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
[TBL] [Abstract][Full Text] [Related]
7. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
8. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
[TBL] [Abstract][Full Text] [Related]
9. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Kwon SJ; Ahn D; Yang HM; Kang HJ; Chung SJ
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562835
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
Lade DM; Nicoletti R; Mersch J; Agazie YM
Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
13. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract][Full Text] [Related]
14. Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
Kuban-Jankowska A; Gorska-Ponikowska M; Wozniak M
Anticancer Res; 2017 Jun; 37(6):2893-2898. PubMed ID: 28551626
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
Zhen XL; Yin WH; Tian X; Ma ZJ; Fan SM; Han JR; Liu S
Bioorg Med Chem; 2015 May; 23(10):2562-7. PubMed ID: 25865131
[TBL] [Abstract][Full Text] [Related]
16. Discovery of allosteric SHP2 inhibitors through ensemble-based consensus molecular docking, endpoint and absolute binding free energy calculations.
Jama M; Ahmed M; Jutla A; Wiethan C; Kumar J; Moon TC; West F; Overduin M; Barakat KH
Comput Biol Med; 2023 Jan; 152():106442. PubMed ID: 36566625
[TBL] [Abstract][Full Text] [Related]
17. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
18. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
19. A procedure combining molecular docking and semiempirical method PM7 for identification of selective Shp2 inhibitors.
Rocha SFLS; Sant'Anna CMR
Biopolymers; 2019 Nov; 110(11):e23320. PubMed ID: 31268558
[TBL] [Abstract][Full Text] [Related]
20. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]